Breaking News

DSM Obtains Drug Delivery Tech

DSM Biomedical has obtained an exclusive worldwide license to a drug and biologics delivery system developed by MediVas LLC.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

DSM Biomedical has obtained an exclusive worldwide license to a drug and biologics delivery system developed by MediVas LLC. The technology is based on a next-generation set of polymers exclusively licensed from Cornell University and is the result of research from both Cornell and MediVas. The polymers are biodegradable, biocompatible and bioabsorbable as well as non-inflammatory, allowing greater control over the rate and duration of release of therapeutics. The technology can be used with ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters